Cellectar Biosciences (CLRB) EBT Margin (2011)
Cellectar Biosciences (CLRB) posted EBT Margin of 1945.02% for Q1 2011.
Cellectar Biosciences (CLRB) EBT Margin (2011) Analysis & Trends
Cellectar Biosciences has reported EBT Margin for 1 years, with the latest figure at 1945.02% in Q1 2011.
- Quarterly EBT Margin changed N/A year-over-year to 1945.02% in Q1 2011, while the trailing twelve-month figure through Dec 2011 was 15853.41% (changed N/A YoY) and the FY2011 annual result came in at 102187.31%, down 10006324.0% from the prior year.
- EBT Margin was little changed at 1945.02% in Q1 2011 per CLRB's latest filing.
- Over five years, EBT Margin peaked at 1945.02% in Q1 2011 and troughed at 1945.02% in Q1 2011.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 13.77% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -2.67% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -25.06% |
| 10 | Cellectar Biosciences | 6.63 Mn | 6.63 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2011 | -1,945.02% |